Skip to main content
Monsenso A/S logo

Monsenso A/S — Investor Relations & Filings

Ticker · MONSO ISIN · DK0061277977 LEI · 52990024UWU19T5URJ57 ST Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2023-03-08 Annual Report
Country DK Denmark
Listing ST MONSO

About Monsenso A/S

https://www.monsenso.com/

Monsenso A/S is a technology company that provides a digital health solution for mental healthcare and research. The solution connects individuals, clinicians, and carers to support the prevention, early intervention, and treatment of mental illnesses. The core product is a scalable, configurable platform that functions as a CE-marked Class 1 medical device. It consists of a patient-facing smartphone app that collects self-reported outcomes and objective data from sensors and wearables, and a web portal for clinicians to access this data for remote monitoring and personalized treatment. The platform supports a wide range of conditions, including depression, bipolar disorder, anxiety, and schizophrenia. Monsenso partners with healthcare providers, pharmaceutical companies, and researchers to facilitate remote care, support decentralized clinical trials, and gather real-world evidence.

Recent filings

Filing Released Lang Actions
Monsenso presents annual report for 2022
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2022' and contains comprehensive financial statements (Income statement, Cash flow, Balance sheet, Equity, Notes), a management review, an independent auditor's report, and shareholder information. It covers the full fiscal year 2022, fitting the definition of an Annual Report (10-K). FY 2022
2023-03-08 English
Monsenso presents annual report for 2022
Report Publication Announcement Classification · 95% confidence The document is a short company announcement (5,165 characters) that summarizes the annual performance highlights, business development, and outlook for 2022. Crucially, it explicitly states at the end under 'Attachments' that the actual '2022.Annual.Report.v1.pdf' is an attached file. Following the 'Menu vs Meal' rule, this document is an announcement of the report's publication rather than the full annual report itself. FY 2022
2023-03-08 English
Tegning af nye aktier via fortegningsret
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement (Selskabsmeddelelse nr. 3 - 2023) regarding a rights issue (fortegningsret) and the timeline for subscribing to new shares. It discusses the subscription period and how the upcoming release of the 2022 annual report affects the withdrawal rights of investors. Since this document details the process and timeline for a capital raise (share issuance), it falls under the 'Share Issue/Capital Change' category.
2023-02-28 Danish
Monsenso A/S offentliggør et udbud af nye aktier med fortegningsret for eksisterende aktionærer
Share Issue/Capital Change Classification · 96% confidence The document is a subscription form ('Tegningsblanket') for investors to purchase new shares in Monsenso A/S during a rights issue or capital increase. It provides instructions, terms, and a template for shareholders to submit their orders. Since this document relates to the issuance of new shares and capital changes, it falls under the 'Share Issue/Capital Change' category.
2023-02-21 Danish
Monsenso A/S offentliggør et udbud af nye aktier med fortegningsret for eksisterende aktionærer
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Monsenso A/S regarding a rights issue (offering of new shares to existing shareholders). It details the terms of the capital increase, the subscription price, the subscription period, and the use of proceeds. This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) as it describes the issuance of new shares and changes to the company's capital structure.
2023-02-21 Danish
Forsinket real-world evidence studie indstilles på grund af udfordringer med patientrekruttering
Regulatory Filings Classification · 95% confidence The document is a company announcement (Selskabsmeddelelse) regarding the termination of a real-world evidence study due to patient recruitment challenges. It discusses the impact on financial expectations for 2023 and provides contact information. Since it is a general regulatory announcement regarding company operations and does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2023-01-13 Danish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.